Big Pharma Licensing Growth Slows In 2016
Executive Summary
Big pharma licensing deal volume grew 12% between 2012 and 2016, but according to a new report from Datamonitor Healthcare there were fewer deals and dollars attributed to partnerships in 2016.
You may also be interested in...
Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline
Scrip takes a look at how the South Korean pharma/biotech industry's cross-border deals over the past few years compare with global trends, finding that oncology and diabetes have been the dominant therapeutic areas for the out-licensing of assets, but recent activity and value have declined from a peak in 2015.
Combinations Continue To Drive Immuno-Oncology Deal-Making
The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.
Mid Pharma Companies Show Strength In Dealmaking
Datamonitor Healthcare's mid pharma peer set, a group that boasts efficiency in R&D but still relies on business development for growth, has signed a significant number of alliances over the past six years to build out the pipeline in innovative areas.